Regulus Therapeutics Inc (RGLS)
2.65
-0.04
(-1.49%)
USD |
NASDAQ |
May 03, 16:00
2.65
0.00 (0.00%)
Pre-Market: 20:00
Regulus Therapeutics Net Income (Quarterly): -8.061M for Dec. 31, 2023
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -8.061M |
| September 30, 2023 | -7.824M |
| June 30, 2023 | -7.013M |
| March 31, 2023 | -7.139M |
| December 31, 2022 | -6.795M |
| September 30, 2022 | -7.551M |
| June 30, 2022 | -7.258M |
| March 31, 2022 | -6.719M |
| December 31, 2021 | -7.133M |
| September 30, 2021 | -8.628M |
| June 30, 2021 | -6.034M |
| March 31, 2021 | -6.013M |
| December 31, 2020 | -1.322M |
| September 30, 2020 | -1.524M |
| June 30, 2020 | -6.947M |
| March 31, 2020 | -5.937M |
| December 31, 2019 | -4.893M |
| September 30, 2019 | -5.423M |
| June 30, 2019 | -5.016M |
| March 31, 2019 | -3.26M |
| December 31, 2018 | -8.563M |
| September 30, 2018 | -10.27M |
| June 30, 2018 | -13.85M |
| March 31, 2018 | -16.02M |
| December 31, 2017 | -14.45M |
| Date | Value |
|---|---|
| September 30, 2017 | -15.83M |
| June 30, 2017 | -21.61M |
| March 31, 2017 | -20.02M |
| December 31, 2016 | -20.02M |
| September 30, 2016 | -19.52M |
| June 30, 2016 | -21.09M |
| March 31, 2016 | -21.21M |
| December 31, 2015 | -7.226M |
| September 30, 2015 | -13.00M |
| June 30, 2015 | -21.04M |
| March 31, 2015 | -14.49M |
| December 31, 2014 | -22.17M |
| September 30, 2014 | -9.798M |
| June 30, 2014 | -11.97M |
| March 31, 2014 | -12.74M |
| December 31, 2013 | -1.927M |
| September 30, 2013 | -2.164M |
| June 30, 2013 | -7.348M |
| March 31, 2013 | -7.229M |
| December 31, 2012 | -6.876M |
| September 30, 2012 | -5.685M |
| June 30, 2012 | -2.599M |
| March 31, 2012 | -2.247M |
| December 31, 2011 | -2.015M |
| September 30, 2011 | -1.045M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-8.628M
Minimum
Sep 2021
-1.322M
Maximum
Dec 2020
-6.17M
Average
-6.795M
Median
Dec 2022
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals Inc | 45.80M |
| ADMA Biologics Inc | -17.64M |
| FibroGen Inc | -56.23M |
| Protara Therapeutics Inc | -10.22M |
| Amylyx Pharmaceuticals Inc | 4.731M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 8.30M |
| EPS Diluted (Quarterly) | -0.39 |
| Enterprise Value | 151.06M |
| Earnings Yield | -59.62% |
| Normalized Earnings Yield | -207.55 |